Tildrakizumab (Ilumetri): Discovery, Development to Commercialization Case Study
Brand Name: Ilumetri Biomolecule: Tildrakizumab Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune... Read More
Plaque psoriasis drug Tremfya receives Australian & Brazilian approvals
MorphoSys AG, a late-stage, biopharmaceutical company, announced that country subsidiaries of its licensee Janssen reported that Tremfya (guselkumab) has been approved for... Read More
New Brand Launch: Biocon introducing KRABEVA, a biosimilar Bevacizumab
Posted on24 Nov 2017
Comments0
Biocon Ltd, Asia’s premier biopharmaceuticals company, has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and... Read More
European approval for Roche’s tocilizumab for the treatment of giant cell arteritis (GCA)
Roche, a global pioneer in pharmaceuticals and diagnostics company, announced that the European Commission (EC) has approved Actemra/RoActemra (tocilizumab) for the treatment... Read More
Sanofi and Regeneron got EC approval of Kevzara® (sarilumab) in combo with MTX to treat adult patients with moderately to severely active RA
Posted on28 Jun 2017
TagsMAB, Regeneron, Sanofi, sarilumab, US FDA accepts Sanofi and Regeneron's sarilumab BLA for review
Comments0
Sanofi and Regeneron Pharmaceuticals announced that the European Commission (EC) has granted marketing authorization for Kevzara (sarilumab) in combination with methotrexate (MTX)... Read More
Sun Pharma submitted BLA in USFDA for tildrakizumab to treat plaque psoriasis
Sun Pharmaceutical Industries Ltd, announced the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for tildrakizumab. The... Read More
Otsuka and Teva Sign Licensing Agreement for Japan for Fremanezumab
Posted on15 May 2017
Comments0
Otsuka Pharmaceutical Co., Ltd and Teva Pharmaceutical Industries, Ltd. announce an agreement covering Japan for Otsuka to develop and commercialize Teva’s investigational drug candidate fremanezumab... Read More
Zoetis’ Cytopoint is first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use
European Commission has granted marketing authorization for Zoetis’ Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for... Read More
New mAB approval: Avelumab for metastatic Merkel Cell Carcinoma (mMCC)
Posted on25 Mar 2017
Comments0
Biomolecule: Avelumab Brand : Bavencio Class: Monoclonal Antibodies Sub Class: Human anti-PD-L1 antibody of isotype IgG1 USFDA approval Date: 23rd March, 2017... Read More
Mylan settles trastuzumab patent litigation with Genentech and Roche
Development of trastuzumab The drug was first discovered by scientists including Dr. Axel Ullrich and Dr. H. Michael Shepard at UCLA’s Jonsson Comprehensive... Read More